Fortunately, in 2004, Lynch, et al. discovered that NSCLC patients harboring specific EGFR mutations experienced clinical responsiveness to the tyrosine kinase inhibitor (TKI) [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.